Methods and monitoring of treatment with a DLL4 antagonist

摘要

Methods for treating diseases such as cancer comprising administering a DLL4 antagonist, either alone or in combination with other anti-cancer agents, and monitoring for cardiovascular side effects and/or toxicity.

主权项

1. A method of monitoring and reducing the development of cardiotoxicity related to treatment with a delta-like protein 4 (DLL4) antagonist and unrelated to hypertension, comprising:
(a) determining the level of a natriuretic peptide in a sample from a human subject who has cancer and has been receiving treatment with the DLL4 antagonist; (b) comparing the level of the natriuretic peptide in the sample to a predetermined level of the natriuretic peptide; and (c) administering to the subject a therapeutically effective amount of a cardioprotective medication if the level of the natriuretic peptide is above the predetermined level of the natriuretic peptide; and wherein the DLL4 antagonist is an antibody that specifically binds human DLL4.